Incidence of constipation associated with long-acting opioid therapy: A comparative study

被引:50
|
作者
Staats, PS
Markwitz, J
Schein, J
机构
[1] Johns Hopkins Univ, Sch Med, Dept Anesthesiol & Crit Care Med, Div Pain Med, Baltimore, MD 21205 USA
[2] Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21205 USA
[3] Hlth Data Analyt, Princeton, NJ USA
[4] Janssen Pharmaceut Prod LP, Titusville, NJ USA
关键词
constipation; fentanyl transdermal system; morphine; controlled-release; opioid analgesics; oxycodone controlled-release;
D O I
10.1097/01.SMJ.0000109215.54052.D8
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Opioid therapy plays a key role in the management of chronic pain. Constipation is one of the more frequently occurring adverse effects associated with opioid therapy. Methods: A retrospective cohort design study was conducted determine the incidence of constipation in chronic pain patients who received three different long-acting opioids (transdermal fentanyl, oxycodone HCl controlled-release [CR], or morphine CR) for malignant or nonmalignant chronic pain. The data source was claims data (January 1996 through March 2001) from a 20% random sample of the California Medicaid (Medi-Cal) database. Claims data were from adult patients with chronic pain (malignant or nonmalignant) who had no prior diagnosis of constipation and no prior usage of long-acting opioids for at least 3 months before the observation period. Patients were followed for at least 3 months after the initiation of opioid therapy. ICD-9 code for diagnosis of constipation was the main outcome variable. Crude rates of constipation, annual incidence density, relative risk, and adjusted odds ratios were compared. Results: A total of 1,836 patients (601 receiving transdermal fentanyl, 721 receiving oxycodone CR, and 514 receiving morphine CR) were included in the analysis. Crude (unadjusted) rates of constipation were 3.7% for transdermal fentanyl, 6.1% for oxycodone CR, and 5.1% for morphine CR (P > 0.05). Transdermal fentanyl had a lower annual incidence density and risk of constipation than oxycodone CR and morphine CR (P > 0.05). After adjusting for confounding variables, including race and supplemental opioid use, the adjusted risk of constipation was 78% greater in the oxycodone CR group (P = 0.0337) and 44% greater in the morphine CR group (P = 0.2242) than in the transdermal fentanyl group. Conclusion: In this population, patients receiving transdermal fentanyl had a lower risk of developing constipation compared with those receiving oxycodone CR or morphine CR.
引用
收藏
页码:129 / 134
页数:6
相关论文
共 50 条
  • [1] Thienorphine is a potent long-acting partial opioid agonist: A comparative study with buprenorphine
    Yu, Gang
    Yue, Yong-Juan
    Cui, Meng-Xun
    Gong, Ze-Hui
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2006, 318 (01): : 282 - 287
  • [2] Comparative Effectiveness of Short Acting Opioid Escalation and Initiation of a Long-Acting Opioid in Nursing Home Residents
    Nunes, Anthony
    Yuan, Yiyang
    Baek, Jonggyu
    Pawasauskas, Jayne
    Hume, Anne
    Liu, Shao-Hsien
    Lapane, Kate L.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2024, 33 : 141 - 141
  • [3] Alcohol-associated rapid release of a long-acting opioid
    Murray, S
    Wooltorton, E
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 2005, 173 (07) : 756 - 756
  • [4] Long-Acting Opioid Use Reporting
    Boettiger, David C.
    CLINICAL INFECTIOUS DISEASES, 2020, 71 (05) : 1355 - 1355
  • [5] A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia
    Li, Huafang
    Rui, Qing
    Ning, Xiaoping
    Xu, Haiyan
    Gu, Niufan
    PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2011, 35 (04): : 1002 - 1008
  • [6] Comparative Safety of Short-Acting Opioid Dose Escalation and Long-Acting Opioid Initiation in Nursing Home Residents
    Nunes, Anthony P.
    Jung, Heeyoon
    Yuan, Yiyang
    Baek, Jonggyu
    Pawasauskas, Jayne
    Hume, Anne L.
    Liu, Shao-Hsien
    Lapane, Kate L.
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2025,
  • [7] Comparative Safety of Short-Acting Opioid Dose Escalation Versus Long-Acting Opioid Regimen in Nursing Homes
    Jung, Heeyoon
    Nunes, Anthony
    Yuan, Yiyang
    Baek, Jonggyu
    Liu, Shao-Hsien
    Pawasauskas, Jayne
    Hume, Anne
    Lapane, Kate
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2024, 33 : 26 - 26
  • [8] Long-acting antiretroviral therapy
    Soriano, Vicente
    Barreiro, Pablo
    de Mendoza, Carmen
    NATURE MATERIALS, 2020, 19 (08) : 826 - 827
  • [9] Long-acting antiretroviral therapy
    Vicente Soriano
    Pablo Barreiro
    Carmen de Mendoza
    Nature Materials, 2020, 19 : 826 - 827
  • [10] OPIOID WITHDRAWAL PRECIPITATED BY LONG-ACTING ANTAGONISTS
    Kunzler, Nathan M.
    Wightman, Rachel S.
    Nelson, Lewis S.
    JOURNAL OF EMERGENCY MEDICINE, 2020, 58 (02): : 245 - 253